Effects of controlled-release metoprolol on total mortality, hospital- izations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in conges- tive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295 302. S5.2-10. McMurray J.J.V, stergren J, Swedberg K, et al. Effects of cande- sartan in patients with chronic heart failure and reduced left-ven- tricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767 71. S5.2-11. Cohn JN, Tognoni G. A randomized trial of the angiotensin- receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667 75. S5.2-12. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709 17. S5.2-13. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11 21. S5.2-14. Desai AS, McMurray JJ, Packer M, et al. Effect of the angioten- sin-receptor-neprilysin inhibitor LCZ696 compared with enala- pril on mode of death in heart failure patients. Eur Heart J. 2015;36:1990 7. 5.4. Catheter Ablation S5.4.3-1. Zeppenfeld K, Schalij MJ, Bartelings MM, et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isth- mus. Circulation. 2007;116:2241 52. S5.4.3-2. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Eur Heart J. 2015;36:2793 867. S5.4.3-3. Aliot EM, Stevenson WG, Almendral-Garrote JM, et al. 